GLUE — Monte Rosa Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1826457 ·
Last close
$11.71
Market Cap
$999.02M
52W High
$25.77
52W Low
$7.09
ADV30
1,144,424
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 8,968,000 | — | -49,130,000 | -43,397,000 | 691,161,000 | 90,104,000 | 203,880,000 |
| Mar 2026 | 4,210,000 | — | -50,034,000 | -44,503,000 | 736,428,000 | 159,859,000 | 214,512,000 |
| Dec 2025 | 2,781,000 | — | -49,715,000 | -46,135,000 | 448,659,000 | 129,883,000 | 215,603,000 |
| Sep 2025 | 12,768,000 | — | -32,975,000 | -27,081,000 | 459,841,000 | 208,343,000 | 214,004,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,069,000
Investing CF
$-316,785,000
Financing CF
$361,518,000
CapEx
$-8,009,000
Dividends Paid
—
Buybacks
$-357,000
EPS Diluted TTM
$-2.18
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-565,114,000
Inventory
—
Receivables
$4,920,000
ST Investments
$531,000,000
EBIT TTM
$-181,854,000
Pretax Income TTM
$-163,974,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$28,727,000
EBITDA
$-173,728,000
Free Cash Flow
$-74,449,752
Enterprise Value
$617,242,560
Total Cash
$621,104,000
Total Debt
$37,987,000
Shares Out
85,313,401
Trailing EPS
$-1.75
Book Value
$5.72
ROE
-42.7%
ROA
-21.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 123,672,000 | -54,208,000 | -38,626,000 | 448,659,000 | 215,603,000 | 233,056,000 | -22,798,000 |
| Dec 2024 | 75,622,000 | -81,112,000 | -72,700,000 | 438,732,000 | 215,796,000 | 222,936,000 | 41,996,000 |
| Dec 2023 | 0 | -143,311,000 | -135,352,000 | 303,755,000 | 124,505,000 | 179,250,000 | -43,802,000 |
| Dec 2022 | 0 | -112,384,000 | -108,501,000 | 342,389,000 | 70,976,000 | 271,413,000 | -92,466,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.87
Max Pain — expiry 2026-10-16
max pain strike: $12.50 · spot: $11.71 · call oi: 3,410 · put oi: 1,452
Expected Move to 2026-10-16:
±$3.23
(27.54%) —
implied range
$8.49 –
$14.94
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ODTX | Odyssey Therapeutics, Inc. | $1.03B | $21.47 | — |
| MGTX | MeiraGTx Holdings plc | $1.07B | $11.11 | — |
| SLBT | SL Science Holding Ltd | $1.08B | $1.93 | — |
| VOR | Vor Biopharma Inc. | $1.08B | $18.31 | — |
| CGEM | Cullinan Therapeutics, Inc. | $918.80M | $14.95 | — |
News headlines (Yahoo Finance, 1h cache)
Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone
2026-09-13 09:29 · Yahoo
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
2026-09-08 11:00 · Yahoo
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-02 20:01 · Yahoo
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
2026-09-01 11:00 · Yahoo
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant P
2026-08-24 11:00 · Yahoo
Monte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal
2026-08-07 07:10 · Yahoo
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
2026-06-29 22:50 · Yahoo
Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy
2026-06-03 18:00 · Yahoo
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention
2026-05-10 00:24 · Yahoo
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 15:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.